Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 10Withdrawn 2Terminated 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 1

Interventions

venetoclax 77Cyclophosphamide 68Cytarabine 59fludarabine 49Azacitidine 45Specimen Handling 36fludarabine phosphate 35Rituximab 34Biopsy 30Methotrexate 28ibrutinib 27Daunorubicin 25Dexamethasone 24Vincristine 23Decitabine 22obinutuzumab 21Etoposide 21acalabrutinib 19Tacrolimus 19Dasatinib 19blinatumomab 18Melphalan 18Prednisone 16Mycophenolic Acid 16Granulocyte Colony-Stimulating Factor 16Busulfan 16Whole-Body Irradiation 15Injections 15Doxorubicin 15pegaspargase 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × glasdegib × Other hematologic neoplasm × Clear all
NCT04231851 2026-03-06

CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia

University of California, Irvine

Phase 2 Active not recruiting
30 enrolled 15 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡